Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Vernakalant or its saltsPDL I APR / 17
VidarabineF1 I SEP / 98
Vigabatrin and its salts and derivativesF1 I SEP / 98
Vilazodone or its saltsPDL I AUG / 15
VinbarbitalC2 I JUN / 02
Vinblastine and its saltsF1 I SEP / 98
Vincristine and its saltsF1 I SEP / 98
Vindesine and its saltsF1 I SEP / 98
Vinorelbine and its saltsF1 I SEP / 98
VinylbitalC2 I JUN / 02
Viomycin and its salts and derivativesF1 I SEP / 98
Virginiamycin or its salts or derivativesPDL I DEC / 18
Vitamin APDL

in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A

I DEC / 13
Vitamin B12 with Intrinsic Factor ConcentrateF1 I SEP / 98
Vitamin DPDL

in oral dosage form containing more than 1,000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by the person of more than 1,000 International Units of Vitamin D

I DEC / 13
Vitamin KF2 except Vitamin K1 and Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less I OCT / 05
Vitamins any parenterals not otherwise included in Schedule I II SEP / 98
Vitamins in injectable form for parenteral nutrition I JAN / 03
Vorapaxar or its saltsPDL I AUG / 16
VoriconazoleF1 I FEB / 07
VorinostatF1 I MAR / 11
Vortioxetine or its saltsPDL

including but not limited to vortioxetine hydrobromide

I DEC / 14
Voxilaprevir or its saltsPDL I SEP / 17
Xanthinol nicotinateF1 I SEP / 98
Xylazine and its saltsF1 I SEP / 98
Xylometazoline and it salts in nasal preparations for pediatric use (0.05%) II SEP / 98
Xylometazoline and its salts in nasal preparations for adults (0.1%) U
Xylose II SEP / 98
Yellow Fever vaccine I FEB / 02
Yohimbine and its saltsF1 I SEP / 98
Zafirlukast and its saltsF1 I SEP / 99
Zalcitabine and its saltsF1 I SEP / 98
Zaleplon or its salts or its derivativesPDL I NOV / 18
Zanamivir and its salts and derivativesF1 I DEC / 01
ZeranolC3 I SEP / 98
ZidovudineF1 I SEP / 98
Zinc chloride in injectable form for parenteral nutrition I JAN / 03
Zinc sulfate in injectable form for parenteral nutrition I JAN / 03
Ziprasidone and its saltsF1 I MAY / 09
Zoledronic acid and its salts and derivativesF1 I DEC / 02
Zolpidem and any salts thereofTS I JAN / 03
Zomepirac and its saltsF1 I SEP / 98
Zopiclone and its saltsF1 I SEP / 98
ZucapsaicinPDL I DEC / 13
Zuclopenthixol and its salts and derivativesF1 I SEP / 98
a - MethylthiofentanylN I JUN / 02
alpha1- proteinase inhibitor (human) I JAN / 06
p-FluorofentanylN I JUN / 02

1948 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled